Skip to content
MARKETS / NASDAQ / TLRY
NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · LARGE CAP

Tilray Brands, Inc. TLRY

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$915.5M
▲ 11.5% YoY
$-121.4M
In brief

What this company does

Tilray Brands, Inc. produces, markets and sells beverages; cultivates, produces, distributes and sells both medical and adult-use cannabis products; purchases, resells and distributes pharmaceutical and wellness products; and produces, markets and distributes hemp-based food and other wellness products. It is headquartered in Leamington and New York, with operations in Canada, the United States, Europe, Australia, and Latin America. As of May 31, 2026, it had approximately 3,595 employees worldwide. It reports its operating results in four reportable segments: Beverage, Cannabis, Distribution, and Wellness. Tilray Brands, Inc. was incorporated on January 24, 2018.

Written from the business description in Tilray Brands, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 28 July 2026. Every sentence was checked against that document before publication.

Growth
USD 915.5M
Revenue, FY2025 · full 10-year series below
Revenue $B Net income $B
FY2025 · Revenue 0.9 · Net income -0.1
0.4B0.8B-0.8B-1.6B2016201720182019202020212022202320242025
Compound annual growth
+13.4%
+12.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +12.3% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−11 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -6.9% · Net -11.5%
-100%-200%2016201720182019202020212022202320242025
ROE
FY2025 · ROE -7.8%
-100%-200%-300%2016201720182019202020212022202320242025

Each USD of equity lost 8 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -127.5
-80M-160M2016201720182019202020212022202320242025

Total assetsUSD 2.3B
EquityUSD 1.6B
CashUSD 226.0M
Gross debtUSD 8.8M
Net debtUSD -217.2M
Current ratio2.21×

The company holds more cash than debt.

The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016
Revenue $B0.90.80.80.60.60.50.40.20.00.0
Operating income $B−0.1−2.3−0.2−1.4−0.6−0.1−0.1−0.1−0.0−0.0
EBITDA $B····−0.5−0.1−0.1−0.1−0.0−0.0
Income tax $B0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0··
Net income $B−0.1−2.2−0.2−1.5−0.5−0.4−0.1−0.0−0.0−0.0
Free cash flow $B·−0.1−0.1−0.0−0.2−0.1−0.2−0.2−0.0−0.0
EPS, diluted $−1.09−24.56−3.30−2.35−0.99−1.36−0.47−0.18−0.10−0.11
Dividend / sh $··········
Payout %··········
ROE %−7.8−88.3−7.2−37.7−10.8−12.9−14.2−26.0·−311.8
Shares out B0.131.060.830.660.530.45····

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Provenance
Company facts, as filed
How we verify · 0 failures in 48 reconciliationsAUDITED

Reconciled in 10 of 19 fiscal years. 47 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsMay 31
Data on record since2016

Share this section

Download image